Johnson & Johnson Unit Gets European OK for Preventive Ebola Vaccine
July 01 2020 - 10:23AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson on Wednesday said the European Commission
approved the Ebola vaccine regimen from its Janssen Pharmaceutical
Cos. unit for the prevention of the disease caused by the Zaire
ebolavirus species in individuals ages one and older.
J&J said Janssen is now collaborating with the World Health
Organization on vaccine pre-qualification, which it said should
help accelerate registration of the regimen in African countries
and facilitate broader access to those most in need.
The regimen includes Ad26.ZEBOV, based on Janssen's proprietary
AdVac viral vector technology, as the first dose, and MVA-BN-Filo,
based on Bavarian Nordic A/S's MVA-BN technology, as a second dose
administered roughly eight weeks later.
The second-deadliest Ebola outbreak in history, which began in
the Democratic Republic of the Congo in 2018, has infected nearly
3,500 people, killing nearly 2,300 of them.
J&J said a WHO advisory group last year recommended the use
of Janssen's Ebola vaccine regimen as part of efforts to contain
the outbreak, adding that more than 50,000 people in Congo and
Rwanda have been vaccinated to date through the initiative.
J&J noted that the approval marks the first major regulatory
nod for a vaccine developed by Janssen.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 01, 2020 10:08 ET (14:08 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024